Health Care News | Medical Research

AI Platforms Give Inaccurate Information on Crohn Disease, Ulcerative Colitis, and Colorectal Cancer

Current artificial intelligence (AI) platforms ChatGPT and Google’s Bard are not yet a viable source for health-related information for Crohn disease, ulcerative colitis, and colorectal cancer, according to a study to be presented at Digestive Disease Week 2024, taking place May 18-21 in Washington, DC.

Evaluating Prescribing Practices for SZC in Hyperkalemia

Charlotte RobinsonNKF Spring Clinical Meetings 2024 | May 18, 2024

Changes to the ordering plan could help optimize the use of SZC to treat acute hyperkalemia.

Does Renal Denervation Lower Nighttime BP?

Charlotte RobinsonNKF Spring Clinical Meetings 2024 | May 18, 2024

Nocturnal hypertension is common in CKD, but it was unclear if renal denervation could lower nighttime blood pressure.

Markers for Lupus Nephritis

Charlotte RobinsonNKF Spring Clinical Meetings 2024 | May 17, 2024

A patient may have normal creatinine and complements but still have highly active lupus nephritis requiring therapy.

SZC for Hyperkalemia After Adrenalectomy

Charlotte RobinsonNKF Spring Clinical Meetings 2024 | May 17, 2024

Severe hyperkalemia after adrenalectomy is rare but can be managed medically with sodium zirconium cyclosilicate (SZC).

Bemarituzumab Plus mFOLFOX6 Improves PFS, OS Rates in Gastric Cancers

Emily MenendezGastric Cancer | May 17, 2024

Bemarituzumab is a humanized monoclonal antibody that is selective for FGFR2b.

Age, Male Sex Associated With Development of Lupus Nephritis

Rebecca AraujoLupus | May 17, 2024

A study assessed factors associated with kidney involvement in patients with systemic lupus erythematosus.

2-Year Safety, Efficacy of Sparsentan for IgA Nephropathy

Charlotte RobinsonNKF Spring Clinical Meetings 2024 | May 17, 2024

Sparsentan demonstrated meaningful benefits for preservation of kidney function compared with irbesartan over 2 years.

Continuation of JAK Inhibitor Therapy Prevents Relapse in Patients With Ulcerative Colitis

Rob DillardDDW 2024 | May 17, 2024

Patients with refractory UC who are treated with JAKi and withdrawal from therapy have high rates of relapse.

DocWire Content Partners

CardioNerds

Gain insights from The CardioNerds, a group of cardiology experts who aim to democratize cardiovascular education.

The Fellow on Call

Fundamentals, core concepts, and important management approaches in the field of hematology and oncology

Healthcare Unfiltered

Dr. Chadi Nabhan, a renowned voice in hematology and oncology, tackles a multitude of relevant health care topics.

The Oncology Brothers

Drs. Rohit Gosain and Rahul Gosain discuss practice-changing data and standards of oncology care.

Practice Tips With Dr. Lichaa

Dr. Hady Lichaa is an interventional cardiologist specializing in complex coronary interventions.

Rheumatology Rounds With Dr. Maheswaranathan

Review important issues in the rheumatology space, including lupus, rheumatoid arthritis, and more, from Dr. Maheswaranathan.

Powered by DocWire News

GI Oncology Now is the leading medical news resource for practicing oncologists and health care providers treating gastrointestinal malignancies, offering the latest study data and research breakthroughs related to colorectal, gastric, liver, pancreatic, and esophageal cancers.

Heme Today produces the latest news and research for hematologists and oncologists focused on blood disorders such as clotting, red and white blood cell, and iron disorders, including conference highlights, late-breaking research, interviews with leaders in the field, and more.

A medical news property for practicing oncologists treating lung malignancies, Lung Cancers Today features breaking news, commentary, expert interviews, and data analysis to inform providers on the latest research and most effective clinical practices in the lung cancers space.

Nephrology Times delivers the latest news in nephrological treatments and technologies, curating content from clinical trials, conference highlights, and perspectives from key opinion leaders, with the goal of better informing care decisions and improving patient outcomes.

The Latest From GI Oncology Now

Bemarituzumab Plus mFOLFOX6 Improves PFS, OS Rates in Gastric Cancers

Emily MenendezGastric Cancer | May 17, 2024

Bemarituzumab is a humanized monoclonal antibody that is selective for FGFR2b.

Robotic Radical Surgery Offers Benefits for Patients With Rectal GISTs

Emily MenendezGIST | May 16, 2024

Rectal gastrointestinal stromal tumors are rare, making up only 0.1% of all rectal neoplasms and about 5.0% of all GISTs.

Investigating Absorbed Dose Response in 177Lu-DOTATATE for GEP-NETs

Katy MarshallGEP-NETs | May 15, 2024

Researchers can quantify absorbed doses through serial postinfusion scintigraphy measurements of the γ-emissions.

Feasibility of Personalized Neoantigen Vaccines Plus Pembrolizumab for Advanced HCC

Mark Yarchoan, MDUnresectable HCC | May 15, 2024

Dr. Yarchoan details neoantigen-specific T cell responses assessed in the study.

Modified Gustave Roussey Immune Score Detects ICI Response in BTC

Emily MenendezBile Duct Cancer | May 14, 2024

Determining which patients can benefit the most from immunotherapy remains elusive.

Effects of PD-1 Inhibitors on Real-world Treatment Patterns, Outcomes in Advanced HCC

Katy MarshallUnresectable HCC | May 13, 2024

Researchers used descriptive statistics to analyze first-line treatment patterns.

The Latest From Heme Today

Pharmacokinetic-Guided Prophylaxis Feasible for Hemophilia A, B

Leah LawrenceHemophilia | May 14, 2024

Analysis shows pharmacokinetic-guided dosing may be effective for guiding prophylactic factor concentrate therapy.

Repeated Desmopressin Dosing Yielded Decreasing Responses in Nonsevere Hemophilia A

Leah LawrenceHemophilia | May 14, 2024

Compared with before surgery, the percentage of factor VIII increase was 42.9% at day one and 36.4% on day two.

Study Examines Factors Linked With Bleeding Risk in Severe Hemophilia

Leah LawrenceHemophilia | May 10, 2024

Free tissue factor pathway inhibitor levels were associated with thrombin generation in patients with severe hemophilia.

First Patient Receives Lyfgenia Gene Therapy for SCD

Melissa BadamoSickle Cell Disease | May 8, 2024

The gene therapy, which costs $3.1 million, was approved by the FDA in December 2023.

Exa-Cel Sustains Promising Efficacy as SCD Treatment in Phase III Trial

Patrick DalySickle Cell Disease | May 2, 2024

Phase III data from the CLIMB SCD-121 trial verified the efficacy of exa-cel in eliminating vaso-occlusive crises in SCD.

What Are the Risk Factors for Pain Crisis in Patients With SCD After HSCT?

Melissa BadamoSickle Cell Disease | May 2, 2024

Age, weight, graft failure, and donor type are some predictors of pain crisis after HSCT in patients with SCD.

Expert Interviews

Network Websites

GU Oncology Now delivers the latest news in genitourinary oncology therapeutics, clinical trials, conference coverage, and research data, highlighting important advancements in treatments and technologies to better inform providers' decisions and improve patient outcomes.

Blood Cancers Today provides hematologists and oncologists with news, education, and research relevant to their patients and practices. Featuring the latest clinical updates from all facets of the specialty, it offers insights and exclusive interviews from experts in the field.

Cancer Nursing Today delivers critical news, research, and commentary to support oncology nurses throughout their education and careers. Its goal is to advance oncology treatments and care practices and promote the nurse’s role in enhanced patient outcomes and quality of life.

MashupMD is an innovative medical news and social media aggregator. The platform is optimized to deliver rapid access to the latest headlines in health care and collections of key medical content based on what health care professionals around the world are reading and sharing.

Urban Health Today is the leading independent news source that provides urban health care professionals with relevant research and policy developments that impact patients and their practices. Its coverage focuses on clinical, social, and environmental health disparities.